Foster Dykema Cabot & Co. Inc. MA Sells 5,778 Shares of Merck & Co., Inc. (NYSE:MRK)

Foster Dykema Cabot & Co. Inc. MA lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 7.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 69,066 shares of the company’s stock after selling 5,778 shares during the quarter. Merck & Co., Inc. makes up approximately 0.6% of Foster Dykema Cabot & Co. Inc. MA’s portfolio, making the stock its 24th largest holding. Foster Dykema Cabot & Co. Inc. MA’s holdings in Merck & Co., Inc. were worth $3,886,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Merck & Co., Inc. by 1.7% during the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after purchasing an additional 3,312,459 shares during the last quarter. BlackRock Inc. lifted its holdings in Merck & Co., Inc. by 1.0% during the second quarter. BlackRock Inc. now owns 184,997,390 shares of the company’s stock valued at $11,856,484,000 after purchasing an additional 1,834,500 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Merck & Co., Inc. by 3.1% during the second quarter. Franklin Resources Inc. now owns 27,019,572 shares of the company’s stock valued at $1,731,684,000 after purchasing an additional 801,033 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in Merck & Co., Inc. by 7.5% during the third quarter. Ameriprise Financial Inc. now owns 23,515,877 shares of the company’s stock valued at $1,505,621,000 after purchasing an additional 1,631,013 shares during the last quarter. Finally, Boston Partners lifted its holdings in Merck & Co., Inc. by 0.8% during the third quarter. Boston Partners now owns 18,730,874 shares of the company’s stock valued at $1,199,338,000 after purchasing an additional 145,744 shares during the last quarter. Institutional investors own 74.63% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 5,000 shares of the stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $58.00, for a total transaction of $290,000.00. Following the transaction, the insider now directly owns 101,484 shares in the company, valued at $5,886,072. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael J. Holston sold 12,500 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $770,375.00. The disclosure for this sale can be found here. Insiders sold 82,500 shares of company stock worth $5,026,025 over the last ninety days. 0.25% of the stock is currently owned by insiders.

MRK traded down $1.17 on Friday, reaching $53.36. The company had a trading volume of 12,500,816 shares, compared to its average volume of 11,017,954. The company has a market capitalization of $143,868.70, a P/E ratio of 13.41, a P/E/G ratio of 2.25 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.33 and a quick ratio of 1.06. Merck & Co., Inc. has a 52-week low of $52.83 and a 52-week high of $66.41.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. The business had revenue of $10.43 billion for the quarter, compared to the consensus estimate of $10.48 billion. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. Merck & Co., Inc.’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm posted $0.89 earnings per share. equities analysts anticipate that Merck & Co., Inc. will post 4.16 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, April 6th. Investors of record on Thursday, March 15th were paid a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date of this dividend was Wednesday, March 14th. Merck & Co., Inc.’s dividend payout ratio is currently 48.24%.

Several research firms have commented on MRK. Leerink Swann dropped their price objective on shares of Merck & Co., Inc. from $67.00 to $66.00 and set a “market perform” rating on the stock in a report on Wednesday, February 14th. Credit Suisse Group lowered their price target on shares of Merck & Co., Inc. from $67.00 to $66.00 and set an “outperform” rating on the stock in a report on Monday, February 5th. ValuEngine downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. BMO Capital Markets set a $65.00 price target on shares of Merck & Co., Inc. and gave the stock an “outperform” rating in a report on Tuesday, February 13th. Finally, Morgan Stanley increased their price target on shares of Merck & Co., Inc. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $66.47.

TRADEMARK VIOLATION NOTICE: “Foster Dykema Cabot & Co. Inc. MA Sells 5,778 Shares of Merck & Co., Inc. (NYSE:MRK)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/merck-co-inc-mrk-shares-sold-by-foster-dykema-cabot-co-inc-ma.html.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply